FDA panel questions Roche’s Tecentriq-Abraxane combo in breast cancer, but votes to keep approval in place for now

FDA panel questions Roche’s Tecentriq-Abraxane combo in breast cancer, but votes to keep approval in place for now

Source: 
Fierce Pharma
snippet: 

The FDA kicked off its three-day meeting on accelerated approvals of immuno-oncology drugs by picking apart one of the biggest players in the field, Roche’s Tecentriq, a PD-L1 inhibitor that the pharma giant has been counting on to replace sales lost to biosimilar competition on other blockbusters. In the end, advisers voted to keep the med's approval in place while further studies play out.